While cooperation is admirable, we must be aware that the development of a business model for research is a major motivation behind this initiative. The title of the collaboration`s press release is about saving money and is therefore consistent with NHS6`s current priorities. However, efficiency is not the same as efficiency. It appears that the Ministry of Health6 and the NHS (www.rdforum.nhs.uk/) are rapidly transforming into a business, as the guide states, the NHS is “used” in an essentially competitive model,w8 w9 national approved site agreements are helping to speed up the process of awarding industrial trials in the NHS by removing the need for site audits and local law agreements. This allows studies to start earlier, improve the speed of industry-sponsored clinical trials and enable patients with NHS to access innovative treatments more quickly. The range of model location agreements is supported by guidelines that specify the objectives and modalities of the use of the agreement in the development of clinical research contracts supported by pharmaceutical, biopharmaceutical or medical companies. For HRA-authorized studies, HRA`s initial evaluation letter (and HRA authorization letter) specifies the corresponding agreement for each type of site in a study. The document may refer to the declaration of activity and the timing of events, to a model of agreement (for example. B mCTA) or another sponsor document. To address these challenges, the CCTCC mCTA Central Working Group reviewed the MCTA text with the assistance of Innovative Medicines Canada and its affiliates, HealthCareCAN and numerous provincial clinical study groups. Given that many innovative pharmaceutical companies (including members of Innovative Medicines Canada) are participating in an International TransCelerate (CLEAR ) common language evaluation and reconciliation initiative to address five controversial clauses in clinical study contracts, clear clauses have also been set for review. Click here to learn more about these latest developments.

For all clinical trials and clinical investigations (including CTMS, hardware testing, etc.), an agreement signed between the promoter and the host organization is expected before the start of the site search. The Triapartit agreement is intended in the event that the sponsor`s management of a commercial clinical trial is outsourced to a contract research organization. CRO mCIA is supported by the UK Health Services, the National Institute for Health Research, the Association of British Healthcare Industries, the NHS Confederation, the Medical Schools Council, the UK Clinical Research Collaboration, the NHS Research Forum and the Institute for Clinical Research.